Home・Aandelen Lijst・Natera Inc

Natera Inc

Gesloten

SectorGezondheidszorg

321.98 21.19

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

265.23

Max

321.98

Belangrijke statistieken
By Trading Economics
Inkomsten	-132M -85M
Verkoop	31M 697M
EPS	-0.6
Winstmarge	-12.214
Werknemers	6,135
EBITDA	-30M -65M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+19.94% upside

Dividenden
By Acuity
Volgende Winsten	5 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	8.5B 39B
Vorige openingsprijs	300.79
Vorige sluitingsprijs	321.98

Nieuwssentiment

By Acuity

40%

60%

120 / 340 Rangschikking in Healthcare

Natera Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2026, 20:03 UTC

Social Media

News

Natera Inc. shares rise sharply after analyst upgrades and strong earnings. RBC Capital raised its price target to $350, citing robust revenue growth.

6 aug 2026, 23:02 UTC

Social Media

News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

5 aug 2026, 23:01 UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

4 aug 2026, 19:04 UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

3 aug 2026, 19:23 UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

31 jul 2026, 19:46 UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

30 jul 2026, 17:51 UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

29 jul 2026, 22:02 UTC

Natera Inc. shares declined in after-market trading, reversing an initial uptick. The stock is below its 20-day moving average amid cautious market sentiment.

28 jul 2026, 23:46 UTC

Natera Inc shares are higher in after-market hours, showing positive momentum despite remaining below their 20-day moving average after recent declines.

27 jul 2026, 19:46 UTC

News

Natera Inc's shares are lower today, reflecting broader market trends amid a significant drop in crude oil prices affecting sentiment across sectors.

24 jul 2026, 18:46 UTC

News

Natera Inc's shares are lower, retracing from earlier highs amid broader market dynamics and a drop in oil prices affecting various sectors.

22 jul 2026, 18:36 UTC

News

Natera Inc shares are lower following a JAMA study showing its Signatera test's effectiveness for Merkel cell carcinoma, despite favorable sensitivity results.

21 jul 2026, 18:36 UTC

Natera Inc shares are higher, reflecting positive sentiment in U.S. markets amid strong earnings from companies like General Motors and Novartis.

20 jul 2026, 18:16 UTC

News

Natera Inc. shares are lower today, despite positive developments expanding access to its Prospera transplant test and increased revenue from higher testing volumes.

Peer Vergelijking

Prijswijziging

Natera Inc Prognose

Koersdoel

By TipRanks

19.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 318.29 USD 19.94%

Hoogste 375 USD

Laagste 249 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Natera Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Gebaseerd op 19 analisten die aandelenratings hebben gegeven aan Natera Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

120 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.